Literature DB >> 902453

Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.

M Homeida, C Roberts, R A Branch.   

Abstract

The pharmacokinetics and pharmacodynamics following administration of furosemide (40 mg intravenously) have been studied before and after treatment with probenecid (0.5 gm orally every 6 hr for 3 days) and spironolactone (200-mg initial oral dose followed by 50 mg every 6 hr for 3 days) in 6 normal male subjects. Urine losses during each study period were replaced with saline-dextrose-KCl intravenously. The study was performed with the use of a Latin-square design. Probenecid pretreatment induced significant reductions in renal clearance of furosemide by 78%, the extrarenal clearance by 56%, and the volume of distribution by 52%. As a consequence, furosemide half-life was increased by 54%. Probenecid significantly reduced the rate of sodium excretion at all plasma concentrations of furosemide, but the ratio between urinary furosemide concentration and urinary sodium concentration was not altered. Since the proportion of furosemide excreted unchanged in the urine was not markedly changed, total diuretic response was not influenced by probenecid. There was no evidence of any pharmacokinetic interaction between spironolactone and furosemide. The relationship of furosemide kinetics to dynamics observed in these studies confirms that, in man, the diuretic response is determined by drug that reaches the renal tubule rather than the drug level in plasma.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 902453     DOI: 10.1002/cpt1977224402

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

Review 1.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit.

Authors:  V Pichette; D Geadah; P du Souich
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of frusemide.

Authors:  R E Cutler; A D Blair
Journal:  Clin Pharmacokinet       Date:  1979 Jul-Aug       Impact factor: 6.447

Review 5.  Resistance to loop diuretics. Why it happens and what to do about it.

Authors:  D C Brater
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

6.  Effect of probenecid on excretion and natriuretic action of furosemide.

Authors:  F Andreasen; B Sigurd; E Steiness
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

7.  The pharmacokinetics of frusemide are influenced by age.

Authors:  F Andreasen; U Hansen; S E Husted; J A Jansen
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

8.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

9.  The influence of co-administered organic acids on the kinetics and dynamics of frusemide.

Authors:  D K Sommers; E C Meyer; J Moncrieff
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

10.  Determinants of the diuretic response to furosemide in infants with congestive heart failure.

Authors:  T P Green; B L Mirkin
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.